Simcyp Limited announced that it has released the latest version of its flagship simulator, further enhancing its position in modeling and simulation of drug-drug interactions (DDIs) in virtual populations.
Zinsser-Analytic and Thales Nano have teamed up to develop a highly flexible automated synthesizer which combines many functions on one platform.
InQ Biosciences announced its plans to launch the InQTM Cell Research System, a fully integrated system that creates a high fidelity in vivo environment for studying stem cells, plus nerve, brain, and other mammalian cells for disease research.
The Automation Partnership (TAP) announced it has begun installations of its CompacT SelecT Advanced Plating Module, an alternative to the CompacT SelecT system which increase the flexibility of the plating system and enable researchers to produce consistent, high quality cell plates, ready for use in transport assays.
A new free, white paper that guides medical device manufacturers in the complicated process of applying new U.S. Food and Drug Administration (FDA) regulations to combination products embedded with pharmaceutical or biologic components is now available.
Sanofi-Aventis and Novalar Pharmaceuticals, Inc. announced that the Marketing Authorization Application for OraVerse has been accepted for review by the regulatory agencies of the United Kingdom, Germany, Italy, France and Spain.
Pain and depression associated with cancer can be debilitating, but symptoms are often unrecognized and undertreated. These can be significantly reduced through centralized telephone-based care management coupled with automated symptom monitoring.
A landmark study is the first to identify a life-or-death "cell competition" process in mammalian tissue that suppresses cancer by causing cancerous cells to kill themselves.
Nabi Biopharmaceuticals announced that it has completed enrollment in the first Phase 3 clinical trial of NicVAX, the company's proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse.
EntreMed, Inc. announced the publication of preclinical data for its Phase 2 oncology drug candidate, ENMD-2076 an Aurora A/angiogenic kinase inhibitor, which demonstrated significant activity against multiple myeloma (MM) cell lines and in MM models in vivo.
PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, announced the introduction of a new GMP compliant radiochemical solution, Lu-177 nuclide.
In any battle, sizing up one's opponent is a critical first step. For researchers fighting a bacterial infection, that means assessing every nook and cranny of the malicious microorganism and identifying which ones to attack.
The number of young people infected with HIV in Africa is falling in 16 of the 25 countries hardest hit by the virus, according to a new report by a U.N. agency.
As the FDA began a two-day meeting to discuss Avandia's future, it became clear that the agency's own scientists are deeply divided. The FDA will ask a panel of outside advisers to untangle the mess of data that has stumped its own scientists for more than three years.